A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Wugen, Inc.
Wugen, Inc.
Celgene
Boehringer Ingelheim
HUYABIO International, LLC.
Kyowa Kirin Co., Ltd.
Atara Biotherapeutics
miRagen Therapeutics, Inc.
Eli Lilly and Company
Bristol-Myers Squibb
GlaxoSmithKline
Progen Pharmaceuticals
Morphotek
GlaxoSmithKline
INSYS Therapeutics Inc